Nasal cavity neoplasm

Summary

Nasal cavity neoplasm (MONDO:0004756) is a cancer and 2 clinical trials. Top therapeutic interventions include cisplatin and bintrafusp alfa. A subtype of nasal cavity disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasal cavity neoplasm
Mondo ID	MONDO:0004756
DOID	DOID:9310
NCIT	C4413
SNOMED CT	126670003
UMLS	C0345630
MedGen	138023
Anatomy (UBERON)	UBERON:0001707
Is cancer (heuristic)	yes

Also known as: nasal cavity neoplasm · nasal cavity neoplasm (disease) · nasal cavity tumor · nasal cavity tumour · neoplasm of nasal cavity · neoplasm of the nasal cavity · tumor of nasal cavity · tumor of the nasal cavity · tumour of nasal cavity · tumour of the nasal cavity

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › otorhinolaryngologic disease › nasal disorder › nasal cavity disorder › nasal cavity neoplasm

Related subtypes (4): rhinitis, nasal cavity polyp, Binder syndrome, choanal atresia

Subtypes (3): nasal cavity cancer, nasal cavity inverting papilloma, benign neoplasm of nasal cavity

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03274414	PHASE2	COMPLETED	A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
NCT05012098	PHASE2	COMPLETED	Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	1
BINTRAFUSP ALFA	3	1